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Background
The Pediatric Dengue Vaccine Initia-
tive (PDVI) is a product development
partnership (PDP) based at the Interna-
tional Vaccine Institute (IVI) in Seoul,
Korea, and is supported by the Bill &
Melinda Gates Foundation. PDPs are
nonprofit entities that seek to accelerate
the development, evaluation, and intro-
duction of vaccines, drugs, devices, diag-
nostics, and other technologies to reduce
the burden of disease in developing
countries. They operate through partner-
ships with public and private organizations
to assemble networks with the needed skills
for the work required to achieve the goal
of disease reduction. PDPs have been
formed for vaccines against malaria,
HIV, tuberculosis, meningitis, and other
diseases, including dengue. PDVI’s mis-
sion is to reduce the burden of dengue
disease by accelerating the development,
evaluation, and introduction of safe, effec-
tive, and affordable dengue vaccines. The
PDVI collaborated with the Developing
Countries’ Vaccine Regulators Network
(DCVRN) to convene two meetings in
2007 concerned with the regulatory issues
that will need to be addressed to license
dengue vaccine(s). (As of January 1, 2011,
the Pediatric Dengue Vaccine Initiative is
renamed the Dengue Vaccine Initiative
Consortium and is composed of IVI, the
Initiative for Vaccine Research of the
World Health Organization, the Interna-
tional Vaccine Access Center of Johns
Hopkins University, and the Sabin Vac-
cine Institute.)
DCVRN is a World Health Organiza-
tion (WHO) initiative involving nine
countries: Brazil, China, Cuba, the Re-
public of South Korea, India, Indonesia,
the Russian Federation, South Africa, and
Thailand. It provides a forum for discus-
sion, advancement of knowledge, and
exposure to policies and procedures per-
taining to oversight of clinical trials and
evaluation of clinical data for registration
of vaccines. The United States Food and
Drug Administration (FDA) and the Eu-
ropean Union European Medicines Agen-
cy for the Evaluation of Medicinal Prod-
ucts (EMA) often participate in meetings of
the DCVRN. In addition, regulatory staff
from several additional dengue-endemic
non-DCVRN member countries (Cambo-
dia, Malaysia, Philippines, and Vietnam)
have participated in the dengue vaccine
sessions at the DCVRN meetings.
The PDVI has also worked with the
Initiative for Vaccine Research (IVR) of
WHO to update guidelines for the clinical
evaluation of dengue vaccines [1]. Because
the work with IVR has been reported
elsewhere [2], the rest of this paper will
address only the work with DCVRN.
The first meeting with DCVRN was
held in April 2007 in Brasilia, Brazil. The
agenda included detailed information on
the epidemiology of dengue, the nature of
the disease, the status of development of
dengue vaccines, and some of the regula-
tory issues that will need to be addressed.
No vaccine developers participated in this
meeting. The second meeting, held in
Bangkok, Thailand, in December 2007,
included several companies that are de-
veloping dengue vaccines. Each of these
companies presented the development
status of their candidates and outlined
the issues that they felt were most
important for testing and ultimate regula-
tory approval of these vaccines.
Dengue Vaccine Development:
The Regulatory Challenges
Thanks to substantial increases in fund-
ing from public and private sources, the
pace of development of vaccines of
concern to developing countries has re-
cently accelerated. As the development of
these vaccines proceeds, a number of
regulatory issues arise.
Dengue is the world’s most important
arboviral disease, affecting over 3.6 billion
people in 124 countries. It results in about
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with more than 6% of cases developing
more serious forms such as dengue
hemorrhagic fever (DHF) and dengue
shock syndrome (DSS), both of which
can result in death [3]. There are no
effective drugs to treat dengue infection
[4]. Vector control for the mosquito
vector, Aedes aegypti, has not proven to be
sustainable or highly effective [5]. Dengue
presents with fever, retro-orbital pain,
myalgia, and petechia. Symptoms may
last for 10–14 days and may progress to
DHF and DSS, leading to death. While
there are no therapeutic drugs, modern
intensive care can reduce case fatality rates
to less than 1%. However, there are no
widely available or reliable rapid labora-
tory diagnostics for the first 4–5 days of
infection, thereby limiting the ability of
physicians to identify at-risk patients early
in the disease [6]. There is consensus that
use of an effective vaccine is the best
option to control this disease [7].
Dengue is prevalent only in tropical
countries where the vector is common.
Clinical trials to assess the safety and
efficacy of dengue vaccines must therefore
be carried out in these developing coun-
tries, and it is likely that the first licensure
of dengue vaccines will occur there.
Dengue diseases are caused by four
related viruses (DENV 1, DENV 2,
DENV 3, and DENV 4). In most
countries, one virus tends to dominate
during a season, but is replaced by other
viruses over several years. Thus, a dengue
vaccine must be effective against all four
viruses, i.e., tetravalent. In addition, there
is the theoretical possibility of an adverse
immune response in individuals not pro-
tected against all four viruses. An individ-
ual protected against one or two of the
four viruses may be subject to a severe
immune response (antibody-dependent
enhancement) if exposed to a virus against
which the individual is not protected,
although the only human studies to assess
this possibility have not observed these
events [8,9]. The challenge of tetravalent
vaccine development is compounded be-
cause of interference among the viruses
and by the lack of an animal model for
dengue infection and disease [6].
Dengue affects a wide age range from
infants through young adults [10–12]. A
dengue vaccine will have to be evaluated
in diverse populations in both the Amer-
icas and the Asia Pacific region and will
have to be delivered in national immuni-
zation programs to infants and in ‘‘catch-
up’’ programs in older age groups.
In recognition of these several compli-
cations, there is high priority to ensure that
developing countries have the capability to
undertake appropriate regulatory review
of proposed clinical studies and of appli-
cations for licensure. It is important that
the national regulatory authorities (NRAs)
of these developing countries have the
information, training, and capabilities to
review and approve applications to under-
take clinical trials and eventually review
and, if appropriate, approve applications
for licensure of dengue vaccines. Involve-
ment of the US FDA and the EMA can be
helpful in assuring a high level of regula-
tory review. In particular, the EMA may
be able to provide scientific advice and
protocol design assistance and assist regu-
latory review through its Article 58 of
regulation 726/2004.
Status of Development of
Dengue Vaccines
Dengue vaccines have been under de-
velopment since the 1940s, but due to the
limited appreciation of global dengue
disease burden and of the potential markets
for dengue vaccines, industry’s interest
languished throughout the 20th century
[13]. However, in recent years the devel-
opment of dengue vaccines has accelerated
dramatically. This changed landscape is
illustrated by the progress in clinical
development of sanofi pasteur’s live-atten-
uated tetravalent chimeric vaccine, which
could be licensed as early as 2014.
It is fortunate that there are several
vaccines under clinical development, because
there is no certainty as to which, if any, of the
candidate vaccines will prove to be safe and
efficacious, and wide access will depend upon
a competitive environment in which several
manufactures are supplying vaccine. For a
recent review of dengue vaccine develop-
ment, see Whitehead et al. [14].
Vaccines in clinical development in-
clude four live attenuated vaccines and
one subunit vaccine under development
by Hawaii Biotech. (In July 2010, Merck
Vaccines & Co. acquired the rights to the
Hawaii Biotech vaccine and has stated its
intention to continue development of the
candidate.) One of the live attenuated
vaccines (GlaxoSmithKline) is a traditional
vaccine prepared by cell passage: three of
the other live attenuated vaccines are
genetic constructs and involve both the
Summary Points
N Because a dengue vaccine should be tetravalent in nature and provide
protection against all four dengue serotypes, regulatory agencies need to
address additional issues associated with multi-valent vaccines such as
interference between the vaccine serotypes.
N Safety assessment needs to account for the potential risk of inducing antibody-
enhanced diseases (antibody-dependent enhancement).
N Because of the varying epidemiology and disease impact in different countries
and regions, dengue vaccines will likely need to be evaluated in diverse
populations initially in both the Americas and the Asia Pacific region.
N Several national regulatory authorities (NRAs) in endemic developing countries
are likely to be engaged in review of both applications for clinical evaluation
and for marketing of vaccines and they should receive support as appropriate.
N Manufacturers can submit a dossier to the European Medicines Agency for the
Evaluation of Medicinal Products (EMA) for review (Scientific Opinion). This is
possible due to the introduction of Article 58 of EMA’s regulation 726/2004
(within which the example of dengue is specifically mentioned). This Opinion
could facilitate the review process by NRAs in developing countries.
Manufacturers may also obtain scientific advice and protocol assistance from
the EMA, which may facilitate later Article 58 review.
N The Developing Countries’ Vaccine Regulators Network recommends that
consideration be given to agreements for joint reviews of clinical trial
applications by similarly affected NRAs and also the review of applications for
licensure in order to accelerate the launch and introduction of dengue vaccines.
The NRAs would need to have access to the necessary expertise to review the
quality and safety aspects of the license application.
N It is critical that improved standardized tests be introduced as soon as possible
for the diagnosis of early infection and for the measurement of immune
protection (requiring identification of a correlate of protection). The World
Health Organization (WHO), through its Expert Committee on Biological
Standardization, can evaluate and standardize such tests; in addition, WHO
and its Collaborating Centers may also help ensure availability of necessary
standards and reagents for use in the field.
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vaccines under development by GlaxoS-
mithKline and sanofi pasteur (live attenu-
ated yellow fever–dengue chimera) have
completed Phase 1 testing and initial
Phase 2 (Phase 2a) testing. The vaccine
developed by the US National Institutes of
Health (NIH) (dengue-dengue chimera
with gene deletion) has been in Phase 1
testing under the auspices of NIH and
entered tetravalent Phase 1 trials in 2010
under the auspices of NIH licensees:
Biological E, Panacea, and Butantan.
The sanofi pasteur vaccine entered ex-
panded Phase 2 (Phase 2b) testing in 2009
in Thailand. The Hawaii Biotech vaccine
entered Phase 1 testing of its monovalent
DEN1 vaccine in 2009. A vaccine (den-
gue-dengue chimera) under development
by Inviragen entered Phase 1 testing in
2010. If the Phase 2b clinical evaluation of
the sanofi pasteur vaccine indicates that
the vaccine is safe and effective, it is
possible that licensure may occur as early
as 2014. Partly because of the requirement
for efficacy against four viruses, the exact
specification and design of Phase 3 trials is
unknown. There remains the possibility
that a vaccine may be licensed on the basis
of safety and efficacy data against one or
perhaps two serotypes. The design of
subsequent Phase 4 trials that may address
efficacy (and safety) with respect to the
other viruses is also unknown. For further
discussion, see the WHO Guidelines [1,2].
Results of the PDVI/DCVRN
Meetings on Dengue Vaccines
Selection of suitable sites for clinical
trials of dengue vaccine candidates is
important, and PDVI has helped to
identify more than ten sites in developing
countries. PDVI is working with these sites
to enhance their capabilities in surveil-
lance and to undertake clinical studies.
Important results have been obtained from
these sites ([15–17] and O. Wichmann, I.
Yoon, S. Vong, K. Limkittikul, R. Gib-
bons, et al., unpublished data), and one
site was chosen by sanofi pasteur for its
Phase 2b trial in Thailand. Key criteria for
consideration in selecting sites are investi-
gator experience, dengue serotype preva-
lence, NRA competence, the implications
of rural versus urban sites, availability of
multi-year longitudinal data on dengue
incidence, and the laboratory’s ability to
detect clinical dengue cases.
Safety monitoring of dengue vaccine
trials will need to be especially diligent in
the initial stages of trials because of
possible immune enhancement in individ-
uals a) who are only partially immunized
and become naturally infected or b) who
have been previously infected and receive
a first vaccine dose. Improved definitions
of adverse events following immunization
are needed. For example, there is a need
to define adverse events 1) caused by
infection occurring between doses of
vaccine, and 2) adverse events caused by
natural virus infection. In addition, there is
a need to validate methods to detect these
events. Improved safety surveillance and
early viral analysis in cases of fever are
needed. These issues have been addressed
for the Phase 2b trial in Thailand.
The NRAs in dengue-prevalent coun-
tries will be requested to consider new
approaches to vaccine development that
may accelerate the process, and the NRAs
must ensure a favorable risk–benefit for
the country. In Brasilia and Bangkok,
there was a discussion on licensure of a
tetravalent dengue vaccine with demon-
strated efficacy and safety against only one
serotype. One potential strategy, under
these conditions, would be to require post-
marketing surveillance for safety and
efficacy against all four viruses.
It is critical that any vaccine being
tested in subsequent studies be the same in
all respects as that being used in earlier
clinical stages. Any changes to the manu-
facturing or formulation steps could result
in the need to repeat the clinical trials or at
the least require complex bridging studies.
A common understanding of ‘‘standard
definitions’’ is important, especially for
lab-based serological tests. Standardized
test methods and the acceptance of
validated international reference standards
for antibody responses and virus typing is
essential. In addition, clearer definitions
are needed for Phase 2a, Phase 2b, and
Phase 3 trials.
Clinical trials should generate data to
help a) understand the science of the
possible severe immune enhanced disease
and b) identify correlates of immunity/
protection that would assist vaccine devel-
opment. The development of an animal
model would be of great benefit but likely
not essential for licensure.
Further effort is required to define
desirable characteristics of vaccine trial
design. This is largely the responsibility of
the manufacturers (in consultation with
competent regulatory agencies) involved in
vaccine development. These include target
age group for immunization, vaccine
dosage schedule, trial duration and fol-
low-up, assessment of possible confound-
ing affects of immunity to other flavivirus-
es, diagnosis and case definition, and long-
term surveillance. Additional issues for
assessing potential trial sites include the
prevalence of the viral strains, influence of
concurrent mosquito control programs,
community involvement, and virological
and diagnostic services.
Phase 3 trials may be undertaken in
some countries based on the safety and
efficacy data from Phase 2 (a or b) trials in
other countries. Responsible NRAs need
to establish procedures for review and
acceptance of second-country data and
will need to assess formulation or regimen
changes dictated by prior clinical trials.
The DCVRN favors the development
of formal procedures for collaboration and
joint review of clinical trial applications
and monitoring including good clinical
practices reviews and inspections by the
responsible NRAs, EMA, and/or US FDA
with facilitation by WHO. The coopera-
tion of the sponsor will be required. The
NRAs would need to have access to the
necessary expertise to review the quality
and safety aspects of the license applica-
tion. The joint review option is also under
consideration for tuberculosis vaccines
[18].
The WHO priority plans for vaccine
development until 2012 include dengue
vaccines. Written WHO standards exist
for live, attenuated dengue vaccines (TRS
932), and several technical consultations
have been held to support the science base
for dengue vaccine evaluation; these
include consultations on dengue vaccine
development [19,20] and guidelines for
plaque-reduction neutralization testing of
human antibodies to dengue viruses [21].
It is critical that improved standardized
tests be introduced as soon as possible for
the diagnosis of early infection and for the
measurement of immune protection (re-
quiring identification of a correlate of
protection). WHO, through its Expert
Committee on Biological Standardization,
can evaluate and standardize such tests; in
addition, WHO, along with its Collabo-
rating Centers, may also help ensure
availability of necessary standards and
reagents for use in the field. In addition,
revised guidelines for the evaluation of
dengue vaccines in exposed populations
have been published [2].
This paper reports on two meetings that
occurred in 2007. In the intervening time
(up to November 2010), there has been no
consideration of the issues discussed in the
paper that would change the conclusions
stated in the paper. WHO and PDVI
convened a meeting in October 2009 in
Bangkok that considered the interactions
between scientific regulatory reviews and
ethics committee reviews of applications to
undertake clinical trials of dengue vaccine.
A key conclusion of the meeting was that
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between scientific and ethical reviews,
but there was no alteration in scientific
or technical views about the regulation of
dengue vaccines. A manuscript summariz-
ing this meeting is in preparation. Also,
since the meetings, two companies (Invira-
gen and Hawaii Biotech) have launched
Phase 1 trials of their vaccines and one
company (sanofi pasteur) has launched
both Phase 2b and Phase 3 trials. These
actions have only served to highlight the
conclusions stated in this paper.
Summary
A number of important issues have been
identified for regulatory review of dengue
vaccines. Plans are being developed to
provide appropriate training and capacity
building for developing country NRAs in
endemic countries.The issuancein2008 by
WHO of Guidelines for the Evaluation of
Dengue Vaccines in Developing Countries
is an important milestone in ensuring a
sound scientific basis for the clinical
evaluation of dengue vaccines. The activ-
ities by manufacturers to develop safe and
efficacious dengue vaccine candidates to-
gether with collaboration among PDVI,
WHO, manufacturers, and developing
countries to support the planned testing,
clinical trial design, and licensure means it
is possible that at least one dengue vaccine
could be licensed within the next 4–5 years.
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